• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

0.01%的超稀释阿托品可减缓儿童和青少年的病情进展。一项为期5年的安全性和有效性研究。

Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness.

作者信息

Diaz-Llopis M, Pinazo-Durán M D

机构信息

Unidades de Retina/Mácula y Oftalmología Infantil, Hospital La Fe, Universidad de Valencia, Valencia, España; Unidad de Oftalmo-Biología Celular y Molecular, Departamento de Cirugía. Facultad de Medicina y Odontología, Universidad de Valencia, Valencia, España; Centros de especialidades calle Alboraya y Juan Llorens, Hospital General de Valencia, , Valencia, España; Unidad de Investigación Oftalmológica "Santiago Grisolía"/FISABIO, e Instituto Oftalmológico de Valencia (IOVA). Consellería de Sanitat de la Generalitat Valenciana, Valencia, España; Sociedad Española de Miopía, España; Sociedad de Investigación en Retina y Visión (SIREV), España.

Unidad de Oftalmo-Biología Celular y Molecular, Departamento de Cirugía. Facultad de Medicina y Odontología, Universidad de Valencia, Valencia, España; Unidad de Investigación Oftalmológica "Santiago Grisolía"/FISABIO, e Instituto Oftalmológico de Valencia (IOVA). Consellería de Sanitat de la Generalitat Valenciana, Valencia, España; Sociedad de Investigación en Retina y Visión (SIREV), España.

出版信息

Arch Soc Esp Oftalmol (Engl Ed). 2018 Apr;93(4):182-185. doi: 10.1016/j.oftal.2017.12.015. Epub 2018 Feb 15.

DOI:10.1016/j.oftal.2017.12.015
PMID:29398233
Abstract

OBJECTIVE

To confirm the clinical security and effectiveness of the daily application of 0.01% superdiluted atropine eyedrops in the progression of myopia in children.

MATERIAL AND METHODS

A total of 200 children 9-12 years of age were randomised into a treated group and a control without treatment. Refraction under cycloplegia was performed.

RESULTS

Myopia progression of the treated group was -0.14±0.35 versus -0.65±0.54 in the control group without treatment. Only 2% of patients were forced to stop treatment due to side effects.

CONCLUSION

Atropine superdiluted atropine 0.01% eyedrops is effective and well tolerated, and reduced myopia progression by 25%.

摘要

目的

确认每日应用0.01%超低浓度阿托品滴眼液对儿童近视进展的临床安全性和有效性。

材料与方法

将200名9至12岁的儿童随机分为治疗组和未治疗的对照组。进行睫状肌麻痹下验光。

结果

治疗组近视进展为-0.14±0.35，未治疗的对照组为-0.65±0.54。仅2%的患者因副作用被迫停止治疗。

结论

0.01%超低浓度阿托品滴眼液有效且耐受性良好，可使近视进展降低25%。

相似文献

1
Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness.0.01%的超稀释阿托品可减缓儿童和青少年的病情进展。一项为期5年的安全性和有效性研究。
Arch Soc Esp Oftalmol (Engl Ed). 2018 Apr;93(4):182-185. doi: 10.1016/j.oftal.2017.12.015. Epub 2018 Feb 15.
2
Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial.0.5%阿托品滴眼液治疗儿童低度近视：一项随机对照试验。
Medicine (Baltimore). 2017 Jul;96(27):e7371. doi: 10.1097/MD.0000000000007371.
3
Atropine 0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia.0.01%阿托品滴眼液可显著减缓儿童近视进展。
J Ocul Pharmacol Ther. 2015 Nov;31(9):541-5. doi: 10.1089/jop.2015.0043. Epub 2015 Jul 28.
4
Low-Concentration Atropine Eyedrops for Myopia in Children.低浓度阿托品滴眼液用于儿童近视
JAMA. 2023 Jun 6;329(21):1885-1886. doi: 10.1001/jama.2023.7286.
5
Low-Concentration Atropine Eyedrops for Myopia in Children-Reply.低浓度阿托品滴眼液用于儿童近视——回复
JAMA. 2023 Jun 6;329(21):1886. doi: 10.1001/jama.2023.7289.
6
Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.低浓度阿托品防治近视进展（LAMP）研究：0.05%、0.025%和 0.01%阿托品滴眼液控制近视的随机、双盲、安慰剂对照临床试验。
Ophthalmology. 2019 Jan;126(1):113-124. doi: 10.1016/j.ophtha.2018.05.029. Epub 2018 Jul 6.
7
Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia - Atropine for the Treatment of Myopia (WA-ATOM) study.澳大利亚儿童停止使用 0.01%阿托品后近视进展情况：西澳大利亚州-阿托品治疗近视（WA-ATOM）研究结果。
Clin Exp Ophthalmol. 2024 Jul;52(5):507-515. doi: 10.1111/ceo.14368. Epub 2024 Feb 23.
8
Effects of 0.05% racanisodamine on pupil size and accommodation.0.05%山莨菪碱对瞳孔大小及调节功能的影响。
Optom Vis Sci. 2010 Dec;87(12):966-70. doi: 10.1097/OPX.0b013e3181fc6445.
9
Topical Atropine for Myopia Control: A Review.局部用阿托品控制近视：综述
Klin Monbl Augenheilkd. 2024 Oct;241(10):1134-1139. doi: 10.1055/a-2307-0363. Epub 2024 May 27.
10
[Atropine for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines].[阿托品预防近视进展——数据、副作用及实用指南]
Klin Monbl Augenheilkd. 2018 Apr;235(4):385-391. doi: 10.1055/s-0043-121982. Epub 2017 Dec 21.

引用本文的文献

1
Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye.0.01%阿托品用于近视管理的停药原因评估：来自土耳其的单中心回顾性研究
Turk J Ophthalmol. 2025 Apr 24;55(2):61-66. doi: 10.4274/tjo.galenos.2025.86584.
2
Myopi-X lenses vs. low-dose atropine in myopia control: a Turkish retrospective study : Study design: retrospective observational study.Myopi-X镜片与低剂量阿托品用于近视控制：一项土耳其回顾性研究：研究设计：回顾性观察研究。
BMC Ophthalmol. 2025 Apr 17;25(1):220. doi: 10.1186/s12886-025-04009-8.
3
Myopia in Children: Epidemiology, Genetics, and Emerging Therapies for Treatment and Prevention.
儿童近视：流行病学、遗传学以及治疗与预防的新兴疗法
Children (Basel). 2024 Nov 27;11(12):1446. doi: 10.3390/children11121446.
4
Myopia Controlling using Low Dose Atropine Eye Drop.使用低剂量阿托品滴眼液控制近视
J Curr Ophthalmol. 2024 Oct 16;36(1):82-88. doi: 10.4103/joco.joco_344_22. eCollection 2024 Jan-Mar.
5
Myopia Control in Caucasian Children with 0.01% Atropine Eye Drops: 1-Year Follow-Up Study.0.01%阿托品滴眼液控制白种人儿童近视：1 年随访研究。
Medicina (Kaunas). 2024 Jun 21;60(7):1022. doi: 10.3390/medicina60071022.
6
Atropine: Updates on myopia pharmacotherapy.阿托品：近视药物治疗的最新进展。
Taiwan J Ophthalmol. 2022 Aug 25;14(2):225-229. doi: 10.4103/tjo.TJO-D-22-00060. eCollection 2024 Apr-Jun.
7
Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study.0.03%阿托品滴眼液控制近视进展的疗效与安全性：一项为期一年的前瞻性临床研究
J Clin Med. 2024 May 30;13(11):3218. doi: 10.3390/jcm13113218.
8
Accommodation in Children after 4.7 Years of Multifocal Contact Lens Wear in the BLINK Study Randomized Clinical Trial.BLINK 研究随机临床试验中，多焦点软性隐形眼镜佩戴 4.7 年后儿童的适应性。
Optom Vis Sci. 2023 Jul 1;100(7):425-431. doi: 10.1097/OPX.0000000000002040. Epub 2023 Jun 24.
9
Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms.低剂量阿托品治疗儿童近视的临床试验（AIM）：一项随机、对照、双盲、多中心临床试验的方案，设两个平行组。
BMJ Open. 2023 Apr 20;13(4):e068822. doi: 10.1136/bmjopen-2022-068822.
10
The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions.阿托品滴眼液在非亚洲地区控制近视的有效性和耐受性
J Clin Med. 2023 Mar 16;12(6):2314. doi: 10.3390/jcm12062314.